XW01397
XW01397 — Introduction of Satralizumab-mwge into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
Billable / specific codeICD-10-PCS
CMS abbreviated title: Introduce Satralizum-mwge in Subcu, Perc, New Tech 7
How XW01397 is built
Every ICD-10-PCS code is seven independent character positions. Each one is a separate decision, and the meaning of a character depends on the positions before it.
- XSectionNew Technology — What family of procedure this is
- WBody systemWhich system it acts on
- 0Root operationThe objective — the verb of the procedure
- 1Body partThe specific site
- 3ApproachHow the site was reached
- 9DeviceWhat was left in place, if anything
- 7QualifierA further distinction where one applies
Codes near XW01397
In CMS’s own ordering, which groups codes that differ by only the last character or two — usually the approach, device or qualifier.
- XT25XE5Monitoring of Kidney using Fluorescent Pyrazine, External Approach, New Technology Group 5
- XW00X27Introduction of Anacaulase-bcdb into Skin, External Approach, New Technology Group 7
- XW01318Introduction of Daratumumab and Hyaluronidase-fihj into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8
- XW01329Introduction of Talquetamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9
- XW01348Introduction of Teclistamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8
- XW0136AIntroduction of Dasiglucagon into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 10
- XW01397Introduction of Satralizumab-mwge into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
- XW013F5Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5
- XW013G6Introduction of REGN-COV2 Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
- XW013H6Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
- XW013K6Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
- XW013L9Introduction of Elranatamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9
- XW013S6Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
- XW013S9Introduction of Epcoritamab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9
- XW013T6Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6